Trials / Completed
CompletedNCT02475486
Role of the ANS Dysregulation in the Persistence of Fatigue in Rheumatoid Arthritis Patients Treated With Anti-TNF
Role of the Sympathetic Nervous System (ANS) Dysregulation in the Persistence of Fatigue in Rheumatoid Arthritis Patients Treated With Anti-TNF (Tumor Necrosis Factor) - a Monocentric Cross-sectional Study
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 50 (actual)
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne · Academic / Other
- Sex
- All
- Age
- 30 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Despite the large therapeutic arsenal available since one decade allowing a strong reduction of inflammation process, rheumatoid arthritis (RA) patients claimed pain, fatigue, sleep problems and other quality of life outcomes. Fatigue reduction during TNF blockers therapy is lower than the strong reduction in RA disease activity. Furthermore, RA patients have higher prevalence of non-inflammatory pain than general population. Fatigue is a real major problem due to 50% of patients considered it as severe. This dissociation between disease activity and fatigue level suggests that fatigue is multifactorial. No consistent explanations for fatigue are currently available.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | VistaO2 | ANS (sympathetic nervous system) parameters are measured by VistaO2 device in RA patients |
Timeline
- Start date
- 2016-02-25
- Primary completion
- 2018-10-08
- Completion
- 2018-10-08
- First posted
- 2015-06-18
- Last updated
- 2019-06-26
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT02475486. Inclusion in this directory is not an endorsement.